Table 3.

Highlighted areas in the AI-generated prognostic maps.

	ALL	PBL-BL	BL-FU1
Tumor Related
Lymph Nodes	46/57 (80.70%)	21/27 (77.78%)	25/30 (83.33%)
— Pericardial	1/2 (50.00%)	1/1 (100.00%)	0/1 (0.00%)
— Mediastinal	42/53 (79.25%)	18/25 (72.00%)	24/28 (85.71%)
— Hilar	16/28 (57.14%)	7/12 (58.33%)	9/16 (56.25%)
— Supraclavicular	16/24 (66.67%)	5/10 (50.00%)	11/14 (78.57%)
— Axillary	3/4 (75.00%)	1/2 (50.00%)	2/2 (100.00%)
Large Lung Masses	33/39 (84.62%)	16/20 (80.00%)	17/19 (89.47%)
Small Lung Nodules	22/26 (84.62%)	8/11 (72.73%)	14/15 (93.33%)
Bone Metastases	14/17 (82.35%)	7/7 (100.00%)	7/10 (70.00%)
Pleural Masses	6/6 (100.00%)	3/3 (100.00%)	3/3 (100.00%)
Liver Metastases	5/6 (83.33%)	2/3 (66.67%)	3/3 (100.00%)
Subcutaneous Lesions	1/1 (100.00%)	—	1/1 (100.00%)
Secondary Comorbidities
Pleural Effusion	25/27 (92.59%)	12/12 (100.00%)	13/15 (86.67%)
Consolidation	20/24 (83.33%)	10/12 (83.33%)	10/12 (83.33%)
— Post-radiation	3/3 (100.00%)	2/2 (100.00%)	1/1 (100.00%)
Atelectasis	16/17 (94.12%)	9/9 (100.00%)	7/8 (87.50%)
— Post-obstructive	7/8 (87.50%)	4/4 (100.00%)	3/4 (75.00%)
Pericardial Effusion	6/8 (75.00%)	2/3 (66.67%)	4/5 (80.00%)
Ascites	1/1 (100.00%)	—	1/1 (100.00%)
General Anatomical Areas
Spine	48/86 (55.81%)	26/43 (60.47%)	22/43 (51.16%)
Thoracic Wall	47/86 (54.65%)	25/43 (58.14%)	22/43 (51.16%)
Periscapular	44/86 (51.16%)	20/43 (46.51%)	24/43 (55.81%)
Shoulder	42/86 (48.84%)	23/43 (53.49%)	19/43 (44.19%)
Neck	41/86 (47.67%)	20/43 (46.51%)	21/43 (48.84%)
Periclavicular	39/86 (45.35%)	19/43 (44.19%)	20/43 (46.51%)
Lung Parenchyma	24/86 (27.91%)	13/43 (30.23%)	11/43 (25.58%)
Axilla	11/86 (12.79%)	6/43 (13.95%)	5/43 (11.63%)
Great Vessels	8/86 (9.30%)	5/43 (11.63%)	3/43 (6.98%)
Breast	3/86 (3.49%)	1/43 (2.33%)	2/43 (4.65%)